Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 – Statsflash

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market areSTEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Request Sample of Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.

Request for a Discount on Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comResearch Blog:https://theglobalhealthnews.com/

Read the rest here:
Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service…

DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs.

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.

As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Amongst other elements, the report includes:

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Regulatory Landscape

6. Stem Cell Therapy Contract Manufacturers In North America

7. Stem Cell Therapy Contract Manufacturers In Europe And Asia-Pacific

8. Partnerships And Collaboration

9. Contract Manufacturing Opportunity Assessment

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Key Performance Indicators

14. Concluding Remark

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/r/jwfp7v

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-contract-manufacturing-market-research-2019-2030-source-of-stem-cells-types-of-stem-cells-size-of-contract-service-provider-company-scale-of-operation-key-regions-300968080.html

SOURCE Research and Markets

See original here:
Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service...

New Stem Cell Research Could Make Cancer Treatments affordable and Effective for Hospitals and Patients – PRNewswire

SAN FRANCISCO, Dec. 2, 2019 /PRNewswire/ -INTELLiSTEM Technologies, a pioneering research company revolutionizing stem cell medicine, is helping to create an affordable future for cancer therapies. Currentcancer cell therapies likeCAR T Cells cost between$350k (USD) and $500k (USD.)INTELLiSTEM expects its Super SentinelCells(SSCs) treatment to be priced between$30-$50k USD. This represents a massive difference in price for hospitals and patients paying or co-paying for their own treatments.

"Older generations of cell therapies require harvesting the cells from the patients, processing them, manufacturing them and then injecting them back into the patient," said Dr. Riam Shammaa, MD Founder and CEO of INTELLiSTEM."Most of those cells can't be grown in large quantities and are very difficult to manufacture, driving the cost way up. Our solution is based on genetically engineering 'off-the-shelf cells 'ready to inject directly into patients. Our cells are easy to grow into billions of cells to treat multiple patients and this drops the cost substantially."

According to Shammaa, the highcurrent cost of cell therapies likeCAR T Cells and dendriticcellsis not only unsustainable(causinga heavy financialburdenfor hospitals acrossNorth America) but is also making life-saving cancer therapies financially inaccessible to millions of patients.

INTELLiSTEM Researchers have created genetically engineered Super Sentinel Cells(SSC's) to effectively target Cancer cells.The SSC's are showing an unprecedented 80% success rate in animal models.The current success rate for existing Cancer cell therapy treatments is 20-40%.

INTELLiSTEM is currently moving into phase one of human trials with the SSC's within the next 12 months.

"We could see practical cures for specific Cancers in as little as 5-7 years," added Shammaa.

See animated video of SSC'shere high-resolution Images also available.

How does the treatment work?

Cancer cells are very good at hiding from the immune system. Essentially, the Super Sentinel Cells are the next generation of antigen-presentingcells, theyshow the immune system where the Cancer cells are hiding in a host and allow the immune system to kick in and attack/kill them.

What Cancers could this effectively treat?

Super Sentinel Cells have the capacity to targethematological and solid cancersdue to their ability to learn the signals and antigens of each cancer. Due to the massive task at hand and to accelerate the progression of multiple Cancer cures, INTELLiSTEM started collaborating with cancer centers across the United States and is also looking to collaborate with research institutions around the world to accelerate the accessibility of the therapy to patients. The SSC's are expected to be effective on solid tumors such as Breast Cancer,Lung Cancer, Melanoma, Prostate Cancer and Lymphomas.

How many treatments are required?

Animal models are showing that 80% of the tested animals survive after one treatment compared to 20% using availablecell therapiesand 0% without treatment, but Shammaa believes that 100% can be achieved with a second injection/treatment of Super Sentinel Cells.

SOURCE INTELLiSTEM Technologies

https://www.intellistemtech.com/

Read the original post:
New Stem Cell Research Could Make Cancer Treatments affordable and Effective for Hospitals and Patients - PRNewswire

Why Are We Still Funding This? The Failure of Embryonic Stem Cell Research – Christianheadlines.com

I certainly dont recommend the cartoon Family Guy, but in a2012 episodethe main character, Peter Griffin, has a stroke that paralyzes half his body. He stumbles into a stem cell research lab and is cured in five minutes. Why arent we funding this? he asks.

Well, the show not only got it exactly wrong, it cheated.

Let me explain. The cartoon never delineates whether the research center uses adult stem cells or embryonic stem cells. That difference is everything. Embryonic stem cells are only acquired by destroying human embryos. Acquiring adult stem cells does not require the death of a human embryo.

You might remember this was a central issue of the 2004 presidential election. Democratic nominee John Kerry led the chorus of outlandish promises for embryonic stem cells, shaming George W. Bushs decision to ban federal funding of embryo destructive research while, for the first time, directing funding for adult stem cell research.

Kerry even claimed that embryonic stem cell research would enable Superman actor Christopher Reeves to get up and walk again. For his decision to fund research that did not require destroying an embryo, George W. was accused of banning stem cell research, which just wasnt true.

Im guessing the Family Guy episode was perpetuating the myth that Bush didnt fund stem cell research. The truth is Bush didnt fund embryo-destructive stem cell research. And, the Obama Administration lifted the Bush-era ban on embryo-destructive research in 2009, forking over between $100 to $200 million a year in federal funding. In 2012, when that Family Guy episode aired, $150 million in federal grants went to embryo-destructive research.

But heres the thing. Despite all the funding dedicated to embryo-destructive research, embryonic stem cells had not yielded a single viable treatment by 2012, but adult stem cellshad. So if Peter Griffin was, in fact, miraculously healed by stem cells, it wasnt because embryos were destroyed in the process.

In fact, seven years and hundreds of billions of dollars later, there are still zero treatments from embryonic stem cells. But,according to the pro-life think tank Lozier Institute,adult stem cell research has made significantly more progress, and shown far more real promise, in treating diseases and conditions than embryonic stem cell research has.

In fact, scores of diseasesand condition are now treated usingadultstem cells, including brain cancer, diabetes, Crohns disease, Parkinsons and multiple sclerosis.

And, in an amazing breakthrough over a decade ago, Japanese scientists learned to reprogram adult stem cells to behave like embryonic stem cells, with the potency to differentiate into many different types of tissue, but without destroying an embryo. In other words, even if it werent so morally problematic, there is simply no reason to destroy embryos in the name of stem cell research anymore.

This raises two questions. First, are we still funding embryo-destructive research? Yes. The question iswhy are we still funding embryo-destructive research? Over $200 million of federal funding still goes to embryo-destructive stem cell research, and it has every year since President Trump has taken office.

In January, Indiana Representative Jim Banks introduced the Patients First Act of 2019, which would have effectively rerouted all National Institutes of Health funding to adult stem cell research. But, in a Democrat-controlled House, it hasnt gone anywhere.

This means executive action is necessary.President Trump has already restrictedNIH experiments using fetal tissue. Its likely hed be willing to end our long national experiment in embryo-destructive research, as well. But he needs to hear from us loud and clear.

Ending this deadly and unethical research, which has brought no miracle cures, should be a cause to unite not just pro-life voters, but all who think taxpayers deserve something for our money.

Download MP3 Audio Here.

BreakPointis a program of the Colson Center for Christian Worldview. BreakPoint commentaries offer incisive content people can't find anywhere else; content that cuts through the fog of relativism and the news cycle with truth and compassion. Founded by Chuck Colson (1931 2012) in 1991 as a daily radio broadcast, BreakPoint provides a Christian perspective on today's news and trends. Today, you can get it in written and a variety of audio formats: on the web, the radio, or your favorite podcast app on the go.

John Stonestreetis President of the Colson Center for Christian Worldview, and radio host ofBreakPoint,a daily national radio program providing thought-provoking commentaries on current events and life issues from a biblical worldview. John holds degrees from Trinity Evangelical Divinity School (IL) and Bryan College (TN),and is the co-author ofMaking Sense of Your World: A Biblical Worldview.

Publication date:December 3, 2019

Photo courtesy:Getty Images/Rost 9D

More here:
Why Are We Still Funding This? The Failure of Embryonic Stem Cell Research - Christianheadlines.com

Stem cell therapy shows promise for the first time in spinal cord injury – News-Medical.net

Researchers have published the results of their work where stem cell therapy has shown promise in a case of spinal cord injury. The results of their case study were published in the latest issue of the journal Mayo Clinic Proceedings last week. The study was titled, Celltop Clinical Trial: First Report From a Phase I Trial of Autologous Adipose-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury.

Early research published in Mayo Clinic Proceedings examines the first case at Mayo Clinic of stem cell therapy tested in humans for spinal cord injury. Image Credit: Mayo Clinic

This was essentially the first case and a Phase I clinical trial to see the safety of the procedure said Mohamad Bydon, a Mayo Clinic neurologic surgeon and the lead author of the study. The team used mesenchymal stem cell treatment for the patient and they added a warning that not all patients may show the same levels of success as this case. Dr. Bydon explained, While in this case, the first subject was a super-responder, others may not respond in the same manner. We do not yet understand all of the necessary biology needed to achieve neurological recovery in paralyzed individuals. One of our objectives in this study and future studies is to better delineate who will be a responder and why patients respond differently.

The team wrote that over 17000 persons in the United States suffer from traumatic spinal cord injury annually and the burden of the injuries affect 291,000 or more annually. These injuries thus form a major socioeconomic burden and cost the health care system over $40 billion including the loss as work force. Regenerative medicine using stem cells have been one avenue that has been explored in the recent years to seek for answers to paralysis caused due to spinal cord injuries. The team wrote that the, adipose tissue represents a readily accessible and viable source of MSCs. Available evidence has shown that adipose tissue derived (AD) MSCs can regulate inflammatory responses and provide a regeneration-permissive environment in animal models of SCI.

This trial, the team wrote, was planned with 10 patients who were paralyzed as a result of traumatic spinal cord injury (SCI). Mesenchymal stem cell therapy was tried on the patients and one of them showed motor as well as sensory benefits from the therapy and did not show any side effects of adverse reactions. They wrote, The CELLTOP study, an ongoing multidisciplinary phase 1 clinical trial conducted at Mayo Clinic (ClinicalTrials.gov Identifier: NCT03308565), is investigating the safety and efficacy of intrathecal autologous AD-MSCs in patients with blunt, traumatic SCI. (AD MSCs - Adipose tissue derived mesenchymal stem cells).

The patient, 53 year old man, Chris Barr, said that he had never hoped to regain motor or sensory functions after his surfing accident. In his recent interview to the media he has said, The prognosis was was bad... And bad meaning, you know, probably a 95 to 97 percent chance that Ill have nothing below my neck. His injury was labelled as American Spinal Injury Association Impairment Scale grade A.

For this procedure where he was the first to sign up, he underwent stem cell therapy which had never been tried before. Stem cells were taken from his own body and in the lab they were coaxed into turning into becoming spine cells. These stem cells were derived from the adipose tissues or fat cells. Authors wrote that 100 million autologous AD-MSCs were then injected back into his spinal cord at the level of the lumbar spine. This was done 11 months after the spinal injury Barr suffered. With regular physiotherapy after the treatment, Barr has regained his senses in the lower limbs and can walk on his own feet, explain the researchers. The patients was tested for any side effects at 3, 6, 12 and 18 months after the injection of the stem cells to his spine.

Authors wrote in conclusion, Thus, in this treated individual with SCI, intrathecal administration of AD-MSCs was feasible and safe and suggested meaningful signs of improved, rather than stabilized, neurologic status warranting further clinical evaluation.

According to Dr. Bydon, despite the fact that not all may respond similarly, this study spkrks hope among hundreds of thousands of individuals who suffer from traumatic spinal cord injuries each year and remain paralyzed for life. Bydon said, The hope is that we will have novel treatments for spinal cord injuries in the coming years that will be different from what we have today. These will be therapies that do not rely upon supportive care, but therapies that rely on science to create a regenerative process for the spinal cord.

Journal reference:

CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose TissueDerived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury Bydon, Mohamad et al. Mayo Clinic Proceedings, https://www.mayoclinicproceedings.org/article/S0025-6196(19)30871-7/fulltext

Read more from the original source:
Stem cell therapy shows promise for the first time in spinal cord injury - News-Medical.net

Why Do We Still Fund Embryonic Stem Cell Research That Exploits Babies and Hasn’t Cured Any Patients? – LifeNews.com

I certainly dont recommend the cartoon Family Guy, but in a 2012 episode the main character, Peter Griffin, has a stroke that paralyzes half his body. He stumbles into a stem cell research lab and is cured in five minutes. Why arent we funding this? he asks.

Well, the show not only got it exactly wrong, it cheated.

Let me explain. The cartoon never delineates whether the research center uses adult stem cells or embryonic stem cells. That difference is everything. Embryonic stem cells are only acquired by destroying human embryos. Acquiring adult stem cells does not require the death of a human embryo.

You might remember this was a central issue of the 2004 presidential election. Democratic nominee John Kerry led the chorus of outlandish promises for embryonic stem cells, shaming George W. Bushs decision to ban federal funding of embryo destructive research while, for the first time, directing funding for adult stem cell research.

Kerry even claimed that embryonic stem cell research would enable Superman actor Christopher Reeves to get up and walk again. For his decision to fund research that did not require destroying an embryo, George W. was accused of banning stem cell research, which just wasnt true.

Im guessing the Family Guy episode was perpetuating the myth that Bush didnt fund stem cell research. The truth is Bush didnt fund embryo-destructive stem cell research. And, the Obama Administration lifted the Bush-era ban on embryo-destructive research in 2009, forking over between $100 to $200 million a year in federal funding. In 2012, when that Family Guy episode aired, $150 million in federal grants went to embryo-destructive research.

But heres the thing. Despite all the funding dedicated to embryo-destructive research, embryonic stem cells had not yielded a single viable treatment by 2012, but adult stem cells had. So if Peter Griffin was, in fact, miraculously healed by stem cells, it wasnt because embryos were destroyed in the process.

In fact, seven years and hundreds of billions of dollars later, there are still zero treatments from embryonic stem cells. But, according to the pro-life think tank Lozier Institute, adult stem cell research has made significantly more progress, and shown far more real promise, in treating diseases and conditions than embryonic stem cell research has.

In fact, scores of diseases and condition are now treated using adult stem cells, including brain cancer, diabetes, Crohns disease, Parkinsons and multiple sclerosis.

Keep up with the latest pro-life news and information on Twitter.

And, in an amazing breakthrough over a decade ago, Japanese scientists learned to reprogram adult stem cells to behave like embryonic stem cells, with the potency to differentiate into many different types of tissue, but without destroying an embryo.In other words, even if it werent so morally problematic, there is simply no reason to destroy embryos in the name of stem cell research anymore.

This raises two questions. First, are we still funding embryo-destructive research? Yes. The question is why are we still funding embryo-destructive research? Over $200 million of federal funding still goes to embryo-destructive stem cell research, and it has every year since President Trump has taken office.

In January, Indiana Representative Jim Banks introduced the Patients First Act of 2019, which would have effectively rerouted all National Institutes of Health funding to adult stem cell research. But, in a Democrat-controlled House, it hasnt gone anywhere.

This means executive action is necessary. President Trump has already restricted NIH experiments using fetal tissue. Its likely hed be willing to end our long national experiment in embryo-destructive research, as well. But he needs to hear from us loud and clear.

Ending this deadly and unethical research, which has brought no miracle cures, should be a cause to unite not just pro-life voters, but all who think taxpayers deserve something for our money.

LifeNews Note: John Stonestreet writes for BreakPoint.org. This article was originally posted here.

Read more:
Why Do We Still Fund Embryonic Stem Cell Research That Exploits Babies and Hasn't Cured Any Patients? - LifeNews.com

Fat grafting improves range of motion in limbs damaged by radiation therapy – Yahoo Finance

A new study released today in STEM CELLS outlines how fat grafting - which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup - also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

DURHAM, N.C., Dec. 3, 2019 /PRNewswire-PRWeb/ --A new study released today in STEM CELLS outlines how fat grafting which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

The tumor-destroying capabilities of radiation therapy can be a life saver for a person suffering from cancer. But it's a therapy that has several unwanted side effects, too, including causing substantial damage not just to cancerous cells, but any healthy tissue in its path. Over time, fibrosis builds up in the treated area which, in the case of an arm, shoulder, or leg, for example, can lead to painful contractures that significantly limit extensibility and negatively impact the person's quality of life.

The Stanford team irradiated the right hind legs of subject mice, which resulted in chronic fibrosis and limb contracture. Four weeks later, the irradiated limbs of one group of the mice were injected with fat enriched with stromal vascular cells (SVCs). These potent cells already naturally exist in fat, but supplementation of fat with additional SVCs enhances its regenerative capabilities. A second group was injected with fat only, a third group with saline and a fourth group received no injections, for comparison. The animals' ability to extend their limb was then measured at baseline and every two weeks for a 12-week period. At the end of the 12 weeks, the hind limb skin underwent histological analysis and biomechanical strength testing.

"Each animal showed significant reduction in its limb extension ability due to the radiation, but this was progressively rescued by fat grafting," reported corresponding author Derrick C. Wan, M.D., FACS. Fat grafting also reduced skin stiffness and reversed the radiation-induced histological changes in the skin.

"The greatest benefits were found in mice injected with fat enriched with SVCs," Dr. Wan added. "SVCs are easily obtained through liposuction and can be coaxed into different tissue types, where they can support neovascularization, replace cells and repair injured issue.

"Our study showed the ability of fat to improve mobility as well as vascularity and appearance," he continued. "We think this holds enormous clinical potential especially given that adipose tissue is abundant and can be easily collected from the patients themselves and underscores an attractive approach to address challenging soft tissue fibrosis in patients following radiation therapy."

Furthermore, said co-author and world-renowned breast reconstructive expert Arash Momeni, M.D., FACS, "Our observations are potentially translatable to a variety of challenging clinical scenarios. Being able to reverse radiation-induced effects holds promise to substantially improve clinical outcomes in implant-based as well as autologous breast reconstruction. The study findings are indeed encouraging as they could offer patients novel treatment modalities for debility clinical conditions.

"Excessive scarring is a challenging problem that is associated with a variety of clinical conditions, such as burn injuries, tendon lacerations, etc. The potential to improve outcomes based on treatment modalities derived from our research is indeed exciting," Dr. Momeni added.

"Skin and soft tissue scarring and fibrosis are well-established problems after radiation. The current study, showing that human fat grafting can normalize the collagen networks and improve tissue elasticity in immune deficient mice, provides molecular evidence for how fat grafting functions," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "The studies indicate that, with the appropriate regulatory approvals, autologous fat grafting could potentially also help human patients recover from radiation-induced tissue fibrosis."

The full article, "Fat grafting rescues radiation-induced joint contracture," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.3115.

Story continues

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

SOURCE STEM CELLS

See the rest here:
Fat grafting improves range of motion in limbs damaged by radiation therapy - Yahoo Finance

Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 – Kentucky Reports

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

See the original post here:
Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 - Kentucky Reports

Researchers show how the ductal system connecting digestive organs is formed – News-Medical.net

A specialized system of ducts transports bile and enzymes from the liver and pancreas to the intestine. In a new study, researchers from the University of Copenhagen have shown how this ductal system is formed. The new knowledge can help understanding how congenital diseases in that part of the body arise.

The body's liver, gallbladder and pancreas are connected by a specialised system of ducts, the so-called hepatopancreatic ductal system, that are leading to the intestine. Bile, digestive enzymes and other secretions flow through the ducts, which are therefore essential for enabling the digestion of food and the absorption of nutrients.

Now, researchers from the University of Copenhagen have investigated how this ductal system forms. The results have been published in the scientific journal Nature Communications.

The new findings may help to better understand rare diseases in the ductal system, such as biliary atresia. This is a disease in children where the ductal network is not properly developed, which can in some cases lead to severe liver damage.

We know very little about diseases such as biliary atresia, where the ducts are blocked or completely absent. In order to understand how and why these diseases occur, it is important to find out how the entire ductal system forms during development."

Elke Ober, Associate Professor and co-author of the study, Novo Nordisk Foundation Center for Stem Cell Biology (DanStem)

'In the study, we show that the ductal system is formed in a multi-step process, with different cell rearrangement and remodeling phases taking place until the ducts are open and fully developed. We have also found an important group of genes that control part of this process,' says co-author and postdoc Ilcim Thestrup, who performed her PhD thesis at DanStem.

The researchers have characterized the formation of the ductal system in zebrafish. The system is formed during embryonic stages. In humans, this takes several weeks, while in zebrafish the ductal system develops in about 48 hours.

Zebrafish resemble humans in many ways: Organ systems, functional cell types and signals controlling developmental processes are highly similar. This together with the fast embryonic development, are the reason why Elke Ober's research group chose to use zebrafish for this study.

In addition to experiments with zebrafish, the researchers examined human tissue samples to investigate if the group of genes, which they found in zebrafish, is also expressed in humans.

'We found a group of genes called EphB and EphrinB in the zebrafish, which instruct part of the development of the ductal system. We have shown that this group is also expressed in humans. This indicates that these genes may play the same or a similar role in the formation of these ducts in humans and if misregulated, they may potentially cause ductal diseases,' says Elke Ober.

Source:

Journal reference:

Thestrup, M.I., et al. (2019) A morphogenetic EphB/EphrinB code controls hepatopancreatic duct formation. Nature Communications. doi.org/10.1038/s41467-019-13149-7.

See the article here:
Researchers show how the ductal system connecting digestive organs is formed - News-Medical.net

Animal Stem Cell Therapy Market forecasted to surpass the value of ~US$ XX Mn/Bn by 2017 – 2025 – The Market Expedition

Assessment of the Animal Stem Cell Therapy Market

Persistence Market Research recently published a report which provides a deep understanding of the various factors that are likely to influence the prospects of the Animal Stem Cell Therapy market in the forecast period 2017 2025. The study takes into account the historical and current market trends to predict the course of the Animal Stem Cell Therapy Market in the upcoming years. Further, the growth opportunities, drivers, and major challenges faced by market players in the Animal Stem Cell Therapy Market are discussed in detail.

The team of analysts at PMR, track the major developments within the Animal Stem Cell Therapy sphere in various geographies. The market share, size, and value of each region are discussed in the report along with explanatory graphs, tables, and figures.

Exciting Prices for New Customers!!!Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.persistencemarketresearch.co/samples/14941

As per the findings of the report, the Animal Stem Cell Therapy Market is slated to grow at a CAGR of ~XX% during the forecast period and attain a market value of ~US$XX by the end of 2029. The report introspects the various factors that are anticipated to have a significant impact on the growth of the Animal Stem Cell Therapy market over the assessment period 2017 2025.

This chapter of the report discusses the ongoing developments of leading companies operating in the Animal Stem Cell Therapy Market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Critical Market Information Enclosed in the Report:

Doubts Related to the Animal Stem Cell Therapy Market Catered to in the Report:

Get Access To TOC Covering 200+ Topics at https://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Customized Report As Per Your Requirements athttps://www.persistencemarketresearch.co/request-customization/14941

Why Opt for Persistence Market Research?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

More here:
Animal Stem Cell Therapy Market forecasted to surpass the value of ~US$ XX Mn/Bn by 2017 - 2025 - The Market Expedition